Haemonetics Überblick
Branche: Medical Instruments & Supplies
Sektor: Healthcare
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equi
Research-Überblick
Letztes Berichtsdatum 2026-08-06Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Haemonetics (HAE): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.
- Börsennotierung
- HAE · NYSE · MIC XNYS
- Land
- United States
- Handelswährung
- USD
- Branche
- Medical Instruments & Supplies
- Finanzdaten
- Jahres- und Zwischenabschlüsse verfügbar
- Letzte Primärquelle
- SEC EDGAR · veröffentlicht 2026-08-06
- Letzter Bericht · SEC EDGAR Veröffentlicht 2026-08-06
- Registrierungsdokument
Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.
Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Haemonetics für einen nachvollziehbaren Research-Prozess ein.
Score
Veröffentlichte Ergebnisse
Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.
Quarterly result summary
Revenue was $339.4M (+5.6% YoY); EPS was $0.72 (reported).
Was sich verändert hat
- Revenue +5.6% YoY to $339.4M; EPS reported to $0.72.
- Capital return update: free cash flow $39M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.
Weitere aktuelle Ergebnisunterlagen
Geprüfte Signal-Evidenz
Aktuelle Nachrichten
Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.
BioCryst gets Japan approval for HAE drug in young children By Investing.com
Headline from Investing.com Australia: BioCryst gets Japan approval for HAE drug in young children By Investing.com.
BioCryst gets Japan approval for HAE drug in young children
Headline from Investing.com: BioCryst gets Japan approval for HAE drug in young children.
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
Headline from GlobeNewswire: BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan.
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve (NASDAQ:BCRX)
Headline from Seeking Alpha: BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve (NASDAQ:BCRX).
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Headline from Yahoo Finance: Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks.
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model (NYSE:HAE)
Headline from Seeking Alpha: Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model (NYSE:HAE).
Gewinn je Aktie
Eigenkapitalrendite
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Eigenkapitalrendite
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Nettomarge
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Nettomarge
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Verschuldung
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Verschuldungsgrad
Unternehmen —
Sektormedian —
Kennzahlen-Chart vorübergehend nicht verfügbar.
Finanzberichte
Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.
Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.